Literature DB >> 28292934

Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer.

Akihisa Kato1, Hiromi Kataoka2, Shigenobu Yano3, Kazuki Hayashi1, Noriyuki Hayashi1, Mamoru Tanaka1, Itaru Naitoh1, Tesshin Ban1, Katsuyuki Miyabe1, Hiromu Kondo1, Michihiro Yoshida1, Yasuaki Fujita1, Yasuki Hori1, Makoto Natsume1, Takashi Murakami4, Atsushi Narumi5, Akihiro Nomoto6, Aya Naiki-Ito7, Satoru Takahashi7, Takashi Joh1.   

Abstract

Peritoneal dissemination is a major clinical issue associated with dismal prognosis and poor quality of life for patients with pancreatic cancer; however, no effective treatment strategies have been established. Herein, we evaluated the effects of photodynamic therapy (PDT) with maltotriose-conjugated chlorin (Mal3-chlorin) in culture and in a peritoneal disseminated mice model of pancreatic cancer. The Mal3-chlorin was prepared as a water-soluble chlorin derivative conjugated with four Mal3 molecules to improve cancer selectivity. In vitro, Mal3-chlorin showed superior uptake into pancreatic cancer cells compared with talaporfin, which is clinically used. Moreover, the strong cytotoxic effects of PDT with Mal3-chlorin occurred via apoptosis and reactive oxygen species generation, whereas Mal3-chlorin alone did not cause any cytotoxicity in pancreatic cancer cells. Notably, using a peritoneal disseminated mice model, we demonstrated that Mal3-chlorin accumulated in xenograft tumors and suppressed both tumor growth and ascites formation with PDT. Furthermore, PDT with Mal3-chlorin induced robust apoptosis in peritoneal disseminated tumors, as indicated by immunohistochemistry. Taken together, these findings implicate Mal3-chlorin as a potential next-generation photosensitizer for PDT and the basis of a new strategy for managing peritoneal dissemination of pancreatic cancer. Mol Cancer Ther; 16(6); 1124-32. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28292934     DOI: 10.1158/1535-7163.MCT-16-0670

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  4 in total

1.  Maltotriose Conjugated Metal-Organic Frameworks for Selective Targeting and Photodynamic Therapy of Triple Negative Breast Cancer Cells and Tumor Associated Macrophages.

Authors:  Yoshie Sakamaki; John Ozdemir; Alda Diaz Perez; Zachary Heidrick; Olivia Watson; Miu Tsuji; Chirstopher Salmon; Joseph Batta-Mpouma; Anthony Azzun; Valerie Lomonte; Yuchun Du; Julie Stenken; Jin Woo-Kim; M Hassan Beyzavi
Journal:  Adv Ther (Weinh)       Date:  2020-06-08

Review 2.  Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.

Authors:  Amina Ben Mihoub; Ludivine Larue; Albert Moussaron; Zahraa Youssef; Ludovic Colombeau; Francis Baros; Céline Frochot; Régis Vanderesse; Samir Acherar
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

3.  FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model.

Authors:  Tamami Higuchi; Takehiko Yokobori; Ryo Takahashi; Tomoharu Naito; Hiromu Kitahara; Takeshi Matsumoto; Chihaya Kakinuma; Shinji Hagiwara; Hiroyuki Kuwano; Ken Shirabe; Takayuki Asao
Journal:  Cancer Sci       Date:  2019-08-01       Impact factor: 6.716

4.  PEGylated Purpurin 18 with Improved Solubility: Potent Compounds for Photodynamic Therapy of Cancer.

Authors:  Vladimíra Pavlíčková; Silvie Rimpelová; Michal Jurášek; Kamil Záruba; Jan Fähnrich; Ivana Křížová; Jiří Bejček; Zdeňka Rottnerová; Vojtěch Spiwok; Pavel Drašar; Tomáš Ruml
Journal:  Molecules       Date:  2019-12-06       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.